Skip to content
Screener

Supernus Pharmaceuticals SUPN Q2 2026 earnings

Reported August 3, 2026 · After market close

Revenue$219.1MBeat by $13.7M
EPS$0.54Beat by $0.12
Revenue estimate$205.3M
EPS estimate$0.42
“As we look to the remainder of the year, we remain focused on disciplined execution and prudent capital allocation, and we believe we are well positioned to build on this momentum.”
Jack Khattar

Next report

Nov 3, 2026 (in a month)
Revenue estimate$218.3M
EPS estimate$0.62

Valuation & ratios

Valuation

as of 10/02/26
See full
Market cap$2.46B-8.7%
Enterprise value$2.31B-10.4%
P/S3.2×-0.8×

FAQ

When did Supernus Pharmaceuticals report Q2 2026 earnings?
Supernus Pharmaceuticals (SUPN) reported Q2 2026 earnings on August 3, 2026 after market close.
What were Supernus Pharmaceuticals's Q2 2026 revenue and EPS?
Supernus Pharmaceuticals reported revenue of $219.1M and eps of $0.54 for Q2 2026.
Did Supernus Pharmaceuticals beat estimates in Q2 2026?
Revenue beat the consensus estimate of $205.3M by $13.7M. EPS beat the consensus estimate of $0.42 by $0.12.
How did Supernus Pharmaceuticals's Q2 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 32.4% from $165.5M a year earlier and eps declined 40.7% from $0.91.
Where can I find Supernus Pharmaceuticals's Q2 2026 SEC filings?
You can read the 8-K earnings release (0001104659-26-089425) and the 10-Q periodic report (0001356576-26-000037) directly on SEC EDGAR. The filing index links above go to sec.gov.